Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
Authors:
- Mariangela ManfrediMMMariangela Manfredi
- Lieve Van HoovelsLHLieve Van Hoovels
- Maurizio BenucciMBMaurizio Benucci
- Riccardo De LucaRLRiccardo De Luca
- Carmela CocciaCCCarmela Coccia
- Pamela BernardiniPBPamela Bernardini
- Edda RussoEREdda Russo
- Amedeo AmedeiAmedeo Amedei
- Serena GuiducciSGSerena Guiducci
- Valentina GrossiVGValentina Grossi
- Xavier BossuytXBXavier Bossuyt
- Carlo PerriconeCarlo Perricone
Open Access
- 19 April 2023
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (4) , 688
Abstract
The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.Keywords
This publication has 61 references indexed in Scilit:
- Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosusBiomarkers, 2012
- Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remissionClinical Chemistry and Laboratory Medicine (CCLM), 2012
- Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2012
- suPAR as a prognostic biomarker in sepsisBMC Medicine, 2012
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- Regulation of cell signalling by uPARNature Reviews Molecular Cell Biology, 2010
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel diseaseDigestive and Liver Disease, 2008
- Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPARStem Cells, 1997
- The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 1995